Skip Navigation


Rheumatology Advance Access originally published online on June 19, 2007
Rheumatology 2007 46(8):1379-1380; doi:10.1093/rheumatology/kem142
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
46/8/1379-a    most recent
kem142v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Collins, K.
Right arrow Articles by Kelly, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Collins, K.
Right arrow Articles by Kelly, C.
Related Collections
Right arrow Rehabilitation
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Reply: Adalimumab-associated pulmonary fibrosis

K. Collins, A. Todd, M. Rynne, J. Hamilton, V. Saravanan and C. Kelly

Department of Medicine, Queen Elizabeth Hospital, Sheriff Hill, Gateshead NE9 6SX, UK

Correspondence to: Dr C. KELLY. E-mail: clive.kelly@ghnt.nhs.uk

The first 10% of the full text of this article appears below.

SIR, We enjoyed reading the letter from Huggett and Armstrong in the October issue of the journal [1], and agree that their case report adds to the mounting body of evidence that suggests . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?